retatrutide nonalcoholic fatty liver disease nash trial Current therapies and new developments in NASH

Retatrutide reduced liver fat by up to 86%. The findings came from a large clinical trial led by Virginia Commonwealth University, which included obese participants with fatty liver disease. Read the story

22.05

★★★★☆4.8 (126)

Retatrutide reduced liver fat by up to 86%. The findings came from a large clinical trial led by Virginia Commonwealth University, which included obese participants with fatty liver disease. Read the story

20.79

★★★★★4.9 (98)

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

29.22

★★★★★5.0 (157)

NASH Drug Development: Seeing the Light at the End of the Tunnel?

28.55

★★★★★4.7 (84)

Retatrutide reduced liver fat by up to 86%. The findings came from a large clinical trial led by Virginia Commonwealth University, which included obese participants with fatty liver disease. Read the story

29.67

★★★★★4.9 (203)

Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge | American Journal of Physiology-Gastrointestinal and Liver Physiology

22.27

★★★★★5.0 (176)

Another Win for GLP-1: Fatty Liver Disease Until now, treatment options for metabolic dysfunction–associated steatohepatitis (formerly called NASH; now MASH) have been extremely limited. In this large Phase 3 trial, researchers tested

26.65

★★★★★4.8 (132)